Abstract: Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.

Abstract: A compound of formula (I): wherein: Y is (CH2)n, where n is from 2 to 4; W1 and W11 are independently selected from OH and ORP, where RP is Me or Et.

Abstract: Provided herein are inhibitors of TNF?, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF? inhibitory compounds for the treatment of diseases or disorders.

Abstract: The present invention is related to a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of aminocarboxymuconate semialdehyde decarboxylase (ACMSD).

Abstract: Provided herein are processes for forming sufentanil citrate from sufentanil base. One process comprises forming sufentanil citrate in the presence of a polar non-aqueous solvent. Other processes comprise forming sufentanil citrate in the presence of water.

Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.

Abstract: The present invention relates to a novel and improved method for preparing 4-amino-5-methylpyridone of the formula (I) which is an intermediate in the preparation of the MR antagonist finerenone.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein R1 is C1-C3alkyl optionally substituted with F, C3-C6cycloalkyl, C1-C3alkoxy; X represents a bond or C1-C3alkylene optionally substituted with OH, ONO, ONO2; R2 is H, OH, ONO, ONO2, C(O)OH, C(O)OC1-C3alkyl, CHO, CN, C1-C3alkoxy, OC(O)H, OC(O)—C1-C3alkyl, C(O)N(R6)OR7, OC1-C3alkylene-C(O)OH, OC1-C3alkylene-C(O)OC1-C3alkyl, OC1-C3alkylene-C(O)N(R6)OR7, S(O0-2)C1-C3alkyl, CR8?N—OR9, CR8?N—NR10R11, CR8?NR12 or CR8?N—ONO2; R3 is C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, C1-C3alkoxy, C3-C6cycloalkyl; C3-C6cycloalkyl, C2-C6alkenyl, C2-C6alkynyl; R4 is C1-C6alkyl optionally substituted with C3-C6cycloalkyl, C1-C6alkoxy, F, ONO, ONO2; C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl; R5 is H, SO2N—R13R14, NHSO2NR13R14; R6 is H or C1-C3alkyl; R7 is H, C1-C3alkyl, C1-C3alkoxy, C1-C3alkyl substituted with phenyl, benzyl or a heterocyclic ring, wherein said phenyl, benzyl or said het

Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.

Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

Abstract: Provided are indole alkaloid compounds in a noni enzyme, wherein the structural formula is shown in the following formula: Provided is a preparation method of the above-mentioned compound and application of the indole alkaloid compound in the noni enzyme in the preparation of an ?-glucosidase inhibitor. The indole alkaloid compound in the noni enzyme provided by the invention has a simple preparation process, low cost and abundant raw material sources.

Abstract: An imide derivative has a structure represented by general formula (1) below. In the general formula (1), a plurality of R1 each independently represent a hydrogen atom or a substituent. At least one R1 represents a group having 4 to 30 carbon atoms. A benzene ring or naphthalene ring optionally further has a substituent, and * represents a position of a substituent that the benzene ring or naphthalene ring optionally has.

Abstract: The application describes methods for making a deuterated dextromethorphan of Formula (I), deuterated dextromethorphan produced by these methods, and pharmaceutically acceptable salts thereof.

Abstract: The present application provides a preparation method of racemic nicotine, including the following steps: Nicotinyl chloride and methylamine are reacted under alkaline conditions to obtain methylnicotinamide, then condensed with monochloroacetone to obtain N-methyl-N-(2-oxopropyl) nicotinamide, then self-aldol condensed to obtain 1-methyl-5-(pyridin-3-yl)-1,2-dihydro-3H-pyrrol-3-one, and finally reduced to obtain racemic nicotine.

Abstract: The present disclosure provides a method for preparing a near-infrared region II fluorescent small molecule. The method utilizes organic full synthesis to construct a novel structured fluorescent probe small molecule, belonging to the fields of chemical sensing technology and fluorescence imaging. Compared with the currently studied fluorescent probe with a benzobisthiadiazole structure, the near-infrared region II fluorescent small molecule has the advantages of simple synthesis method, easy modification, stable structure, high fluorescence quantum yield and the like.

Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2a, X, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNF?, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

Abstract: The present invention relates to a method for preparing dihydroxyammonium 5,5?-bistetrazole-1,1?-diolate. The method for preparing dihydroxyammonium 5,5?-bistetrazole-1,1?-diolate, according to one embodiment of the present invention, comprises the steps of: synthesizing 5,5?-bistetrazole-1,1?-diol dihydrate (1,1?-BTO) from ditetrahydropyranyl diazidoglyoxime (THP-DAG) by using a hydrochloric acid (HCl) solution in a first solvent; and reacting 1,1?-BTO with an amine solution so as to neutralize same and, simultaneously, obtaining dihydroxylammonium 5,5?-bistetrazole-1,1?-diolate (Thomas Klapotke explosive-50, TKX-50).

Abstract: The present application provides a synthesis method for 1-methyl-1H-indazole-6-carboxylic acid. The synthesis method comprises: using 2-fluoro-4-bromobenzaldehyde and methylhydrazine as raw materials to obtain 6-bromo-1-methylindazole by means of an annulation reaction, and then performing a methyl formate reaction and a hydrolysis reaction, so as to obtain the 1-methyl-1H-indazole-6-carboxylic acid. The synthesis method provided in the present application can directly synthesize a 1-position methyl substituted indazole without isomers, thereby avoiding the problem that impurities are difficult to be removed in subsequent separation, thus improving the purity of a product. The yield of the annulation reaction can reach 85%.

Abstract: The invention provides synthetic methods for the preparation of cantharidin and analogs thereof. In one aspect, the invention provides an improved Diels-Alder cycloaddition to generate a key intermediate en route to cantharidin and analogs thereof. In certain embodiments, the new Diels-Alder reaction involves reacting Compound (2) in the presence of furan, and in the absence of acid or increased pressure, in an aprotic polar solvent with slight warming, to yield Compound (1) in favorable yield and exo-endo ratio. In another aspect, the invention also provides a new Diels-Alder reaction between compounds of Formula (III) and furan to yield compounds of Formula (IV), which can then be transformed into cantharidin or analogs thereof. In yet another aspect, the invention describes a new palladium-mediated carbonylation providing another key intermediate en route to cantharidin and analogs thereof. In addition to synthetic methods, present invention also provides compounds (i.e.